ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 275.6 CHF | -0.18% |
|
+0.63% | +5.43% |
| 03:11pm | Nykredit Bank Initiates Coverage on Roche With Buy Recommendation | MT |
| 01:50pm | Nykredit Bank Starts Roche Coverage at Buy | MT |
| Sales 2024 * | 60.61B 67.76B 5,662B | Sales 2025 * | 64B 71.55B 5,978B | Capitalization | 204B 228B 19,054B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.25B 14.81B 1,238B | Net income 2025 * | 14.76B 16.5B 1,378B | EV / Sales 2024 * | 3.6 x |
| Net Debt 2024 * | 14.09B 15.75B 1,316B | Net Debt 2025 * | 9B 10.06B 841B | EV / Sales 2025 * | 3.33 x |
| P/E ratio 2024 * |
14.7
x | P/E ratio 2025 * |
13.3
x | Employees | 1,03,605 |
| Yield 2024 * |
3.91% | Yield 2025 * |
4.02% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More recommendations
More press releases
More news
| 1 day | -0.18% | ||
| 1 week | +0.63% | ||
| Current month | +9.02% | ||
| 1 month | +6.49% | ||
| 3 months | +16.08% | ||
| 6 months | +6.81% | ||
| Current year | +5.43% |
1 week
269.20
278.57
1 month
248.60278.57
Current year
229.80278.57
1 year
229.80299.20
3 years
229.80438.80
5 years
229.80438.80
10 years
211.60438.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 01/03/01 | |
Severin Schwan
CHM | Chairman | 57 | 01/08/01 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 03/15/03 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 01/96/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 275.6 | -0.18% | 4 435 |
| 20/24/20 | 275.6 | -0.14% | 994 |
| 19/24/19 | 276 | +0.95% | 1,217 |
| 18/24/18 | 273.4 | +0.74% | 776 |
| 17/24/17 | 271.4 | -0.90% | 8,053 |
Delayed Quote London S.E., June 21, 2024 at 09:11 pm IST
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250
CHF
Average target price
278.1
CHF
Spread / Average Target
+11.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.63% | 798B | |
| +41.51% | 633B | |
| -5.10% | 356B | |
| +19.90% | 328B | |
| +9.95% | 304B | |
| +17.66% | 244B | |
| +10.75% | 216B | |
| +6.99% | 166B | |
| -3.65% | 157B |
- Stock Market
- Equities
- ROG Stock
- 0QQ6 Stock
